Leiv Takle, MD
Ophthalmology · Griffin, GANPI 1609807445
Payments from drug & device makers
Across 309 payments — averaging $37.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$3K
- Alcon$3K
- Notal Vision, Inc.$1K
- AbbVie$1K
- Carl Zeiss Meditec USA, Inc.$711
- Bausch & Lomb Americas Inc.$645
- plus $2K from 25 others
What the payments were for
- Consulting fees$2,75024%
- Speaking & faculty fees$1,21310%
- Food & beverage$7,38164%
- Education$1381%
- Gifts$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 4 | $2,791 |
| Alcon | 93 | $2,641 |
| Notal Vision, Inc. | 3 | $1,213 |
| AbbVie(2 entities) | 52 | $1,122 |
| Carl Zeiss Meditec USA, Inc. | 9 | $711 |
| Bausch & Lomb Americas Inc. | 39 | $645 |
| Glaukos Corporation | 16 | $478 |
| Novartis | 18 | $367 |
| Sun Pharmaceutical Industries Inc. | 11 | $283 |
| Sight Sciences, Inc. | 12 | $265 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $198 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $188 |
| Amgen(2 entities) | 6 | $119 |
| Kala Pharmaceuticals, Inc. | 3 | $71 |
| Oyster Point Pharma, Inc. | 5 | $68 |
| Dompe US, Inc. | 2 | $54 |
| Harrow Eye, LLC | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Tarsus Pharmaceuticals, Inc. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Sandoz | 1 | $26 |
| Ivantis, Inc | 1 | $25 |
| Thea Pharma Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
| GSK | 1 | $16 |
| NEW World Medical,inc. | 1 | $16 |
| Iridex Corporation | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
| Johnson & Johnson Vision Care, Inc. | 1 | $12 |
| Omeros Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$2,750
- RXSIGHT INJECTOR CARTRIDGE$2,750
- RXSIGHT INJECTOR HANDPIECE$2,750
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,750
- LIGHT ADJUSTABLE LENS (LAL)$2,750
- Clareon$397
- QUATERA 700$331
- LenSx$132
- CIRRUS HD-OCT$127
- Unity$102
How this compares
$11,572 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 275 | $132,957 |
| RestasisCyclosporine | 77 | $75,699 |
| CombiganBrimonidine Tartrate/Timolol | 65 | $23,759 |
| XiidraLifitegrast | 18 | $21,395 |
| CequaCyclosporine | 29 | $18,814 |
| Alphagan PBrimonidine Tartrate | 67 | $18,615 |
| Cyclosporine | 33 | $17,896 |
| RhopressaNetarsudil Mesylate | 31 | $16,959 |
| Brimonidine Tartrate | 145 | $14,191 |
| RocklatanNetarsudil Mesylat/Latanoprost | 25 | $13,752 |
| Latanoprost | 814 | $10,734 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $9,050 |
| Prednisolone Acetate | 181 | $9,042 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $5,061 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 360 | $4,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,122 | $251,030484 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $13 | $30,71156 claims |
| Bausch & Lomb Americas Inc.Xiidra | $645 | $21,39518 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $283 | $18,81429 claims |
| AlconSimbrinza | $2,641 | $9,05021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Griffin
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.